ESG Risks in Global Supply Chains: Regulatory Hotspots ESG Risks in Global Supply Chains: Regulatory Hotspots The regulatory landscape for Environmental, Social, and Governance (ESG) reporting is evolving considerably. By understanding and addressing ESG risks in global supply chains, organizations can improve sustainability and ensure compliance with emerging regulations. This guide offers a step-by-step tutorial for effective ESG reporting consulting with a particular focus on US regulations and frameworks like the CSRD, GRI, SASB, and SEC climate disclosure requirements. Step 1: Understanding the Regulatory Framework for ESG Reporting The first step in effective ESG reporting is understanding the various regulations…

Preparing ESG-Linked Regulatory Filings and Certifications Preparing ESG-Linked Regulatory Filings and Certifications The integration of Environmental, Social, and Governance (ESG) factors into regulatory filings and certifications has gained substantial traction in recent years, especially within the pharmaceutical sector. As stakeholders demand greater transparency, companies must align their operations with evolving ESG expectations, particularly in the context of regulatory compliance. This guide aims to provide a comprehensive, step-by-step tutorial for preparing ESG-linked regulatory filings that meet the requirements of relevant guidelines and standards. Step 1: Understanding the ESG Reporting Landscape Before embarking on ESG-linked regulatory filings, pharmaceutical companies must first develop…

ESG and FDA: Expectations for Environmental Justice in Submissions ESG and FDA: Expectations for Environmental Justice in Submissions In an evolving landscape for pharmaceutical and clinical research professionals, understanding the intersection of Environmental, Social, and Governance (ESG) considerations with regulatory submissions is imperative. The FDA has increasingly recognized the importance of environmental justice, compelling organizations to integrate ESG reporting into their submissions. This article outlines a structured, step-by-step guide to ensure compliance with ESG expectations, particularly in the context of pharmaceutical submissions to the FDA. By adhering to these guidelines, companies can effectively navigate the requirements for ESG reporting consulting…

Third-Party ESG Audits: Preparing the Regulatory Department Third-Party ESG Audits: Preparing the Regulatory Department As regulatory expectations evolve, especially concerning environmental, social, and governance (ESG) issues, organizations in the pharmaceutical sector must be prepared for third-party ESG audits. These audits will play a pivotal role in ensuring transparency, compliance, and sustainability within the industry. This article outlines a comprehensive step-by-step guide for the regulatory department in preparing for third-party ESG audits in the context of ESG reporting consulting. Step 1: Understand ESG Reporting Regulations and Frameworks The first step in preparing for third-party ESG audits is to thoroughly understand the…

Case Study: ESG Integration in Regulatory Strategy of a Biosimilar Company Case Study: ESG Integration in Regulatory Strategy of a Biosimilar Company This detailed guide provides a US-focused commercial-regulatory perspective on integrating Environmental, Social, and Governance (ESG) practices in the regulatory strategy of a biosimilar company. This article outlines a step-by-step approach, ensuring compliance with ESG standards and expectations, addressing the evolving landscape of regulations such as the Corporate Sustainability Reporting Directive (CSRD), Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and SEC climate disclosure requirements. Step 1: Understanding ESG Reporting Essentials The first step in integrating ESG into…

AI and Automation in ESG Data Reporting for Regulatory Teams AI and Automation in ESG Data Reporting for Regulatory Teams As environmental, social, and governance (ESG) considerations become increasingly integral to the pharmaceutical sector, companies are tasked with complying with a myriad of regulatory frameworks. This guide provides a detailed, step-by-step approach to integrate AI and automation into ESG data reporting, particularly focusing on the needs of regulatory teams. The goal is to ensure that firms can efficiently navigate ESG requirements while maintaining adherence to regulations such as the Corporate Sustainability Reporting Directive (CSRD), Global Reporting Initiative (GRI), Sustainability Accounting…

US SEC Climate Disclosure Readiness for Pharma in 2023: Data Controls and Assurance Planning US SEC Climate Disclosure Readiness for Pharma in 2023: Data Controls and Assurance Planning The growing demand for transparency in environmental, social, and governance (ESG) reporting has led the U.S. Securities and Exchange Commission (SEC) to require publicly traded companies, including those in the pharmaceutical sector, to disclose significant climate-related risks. As of 2023, pharma companies must prepare for these regulations with robust data controls and assurance planning. This step-by-step tutorial will guide you through achieving compliance with SEC climate disclosure requirements, focusing on practical actions,…

EU CSRD Compliance for US Pharma Subsidiaries in 2023: Reporting Scope and Evidence Packs EU CSRD Compliance for US Pharma Subsidiaries in 2023: Reporting Scope and Evidence Packs As environmental, social, and governance (ESG) metrics gain significance in the global regulatory landscape, US pharmaceutical subsidiaries operating within the European Union (EU) must navigate the evolving requirements of the Corporate Sustainability Reporting Directive (CSRD). This comprehensive guide aims to provide a structured, step-by-step approach for ensuring compliance with CSRD, focusing on the reporting scope and evidence packs necessary for robust ESG reporting. Step 1: Understanding the CSRD and Its Implications The…

ESG Due Diligence Checklist for Pharma M&A and Licensing Deals in 2023 ESG Due Diligence Checklist for Pharma M&A and Licensing Deals in 2023 In the evolving landscape of pharmaceutical mergers and acquisitions (M&A) and licensing deals, Environmental, Social, and Governance (ESG) considerations are increasingly critical. This article provides a comprehensive, step-by-step ESG Due Diligence Checklist tailored for professionals in the pharmaceutical sector engaged in M&A and licensing transactions. This guide aligns with regulatory standards and best practices, including ESG reporting consulting requirements under various frameworks such as the CSRD, GRI, SASB, and the SEC climate disclosure initiatives. Step 1:…

How to Build Audit-Ready ESG Data Governance for Regulatory and Quality Teams in 2023 How to Build Audit-Ready ESG Data Governance for Regulatory and Quality Teams in 2023 In the evolving landscape of environmental, social, and governance (ESG) considerations, regulatory and quality teams within the pharmaceutical sector face increasing pressures to establish robust data governance frameworks. This step-by-step tutorial is designed to guide organizations in the US on how to build audit-ready ESG data governance. The implications of ESG data on regulatory compliance and operational integrity cannot be overstated. It is essential for organizations to implement structured processes, documentation, and…